VolitionRx Limited (NYSE American: VNRX) provided a corporate update on Tuesday, detailing recent clinical and commercial progress across its diagnostics portfolio. The company announced the submission of a manuscript related to its feline lymphoma diagnostic, which could trigger a $5 million milestone payment under its existing partnership. Additionally, VolitionRx reported continued momentum in licensing discussions with more than a dozen global diagnostic and liquid biopsy companies.
The update also highlighted advancements across the company's pipeline, including validation progress for its Capture-Seq cancer detection platform, expansion of its sepsis-focused Nu.Q NETs program, and ongoing efforts to secure reimbursement in France for its lung cancer assay ahead of anticipated routine clinical use.
"We continue to make strides in both our clinical and commercial initiatives," said a company spokesperson. The feline lymphoma manuscript submission represents a key milestone in the company's animal health diagnostics franchise, which aims to bring simple, cost-effective blood tests to veterinary medicine.
VolitionRx is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, the company develops and commercializes blood tests designed to detect and monitor a range of diseases, including certain cancers and sepsis. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
The company's Capture-Seq platform is designed for early cancer detection using a combination of capture-based enrichment and sequencing. Validation progress on this platform suggests potential for improved sensitivity and specificity in detecting tumor-derived DNA.
The Nu.Q NETs program targets diseases associated with NETosis, a form of cell death implicated in sepsis and other inflammatory conditions. Expansion of this program could address a significant unmet need for rapid and accurate sepsis diagnostics.
In France, VolitionRx is working toward reimbursement for its lung cancer assay, which is expected to support routine clinical use. Securing reimbursement is a critical step for commercial adoption in European markets.
For more information, visit the company's website at https://volition.com/.
